Glucocorticoid treatment decreases liver insulin sensitivity and may modify fatty acid metabolism. We investigated the influence of oral prednisolone on indices for de novo lipogenesis (DNLi), stearoyl-CoA desaturase (SCDi) and Delta 6-desaturase (D6Di) activity in healthy males. In addition, we explored whether the changes may be associated with prednisolone-induced changes in glucose and lipid metabolism and insulin sensitivity.
Thirty-two healthy young males (mean +/- SD age 22 +/- 3 years, BMI 22.4 +/- 1.7 kg/m(2)) were allocated to receive prednisolone 7.5mg/day (PRED7.5; n = 12), prednisolone 30mg/day (PRED30; n = 12), or placebo (n = 8) in a randomized double-blind fashion for 2 weeks. Fatty acid compositions of plasma cholesteryl esters (CE), phospholipids (PL) and triglycerides (TG) were measured at baseline and on day 14. DNLi, SCDi and D6Di were estimated from product/precursor ratios in CE, with DNLi primary deriving from 16:l omega 7/18:2 omega 6, SCDi from 16:omega)7/16:0 and D6Di from 22:6 omega)3/20:5 omega)3. Ratios were also assessed in PL and TG.
In CE, PRED30 increased DNLi by 51.2 [95%CI 14.8; 87.6]%, increased SCDi by 48.6 [18.7; 78.5]%, and decreased D6Di by 57.7 [-91.8; -23.5]% (rho
Prednisolone dose-dependently increases DNLi and SCDi and decreases D6Di in plasma CE, PL and TG in healthy males after 2 weeks. The observed unfavorable effects on fatty acid metabolism were related to the induction of glucocorticoid-induced insulin resistance.
|Number of pages||8|
|Journal||Prostaglandins Leukotrienes and Essential Fatty Acids|
|Publication status||Published - May-2018|
- Fatty acids
- Insulin sensitivity
- Hepatic DNL
- METABOLIC SYNDROME
- HEPATIC LIPOGENESIS
- LIPID CLASSES